Clinical Trial

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2024 (before its estimated March 19, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy (docetaxel+cisplatin+5-fluorouracil, DCF) in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT06463834
Lead Sponsor Fujian Cancer Hospital
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 30 participants
Start Date 2024-03-20
Primary Completion 2025-03-19 (estimated)
Study Completion 2028-03-19 (estimated)
Updated on ClinicalTrials.gov 2024-06-18